Showing results (241-250 of 384) with videos related to

Sort By:
Pageof 39
European Journal of Radiology|January 20, 2016
Is there a role for PET/CT parameters to differentiate thyroid cartilage invasion from penetration?A Tuba Kendi, Amanda Corey, Kelly R Magliocca, et al.
Cancers|October 14, 2023
Review of Outcomes after Salvage Surgery for Recurrent Squamous Cell Carcinoma of the Head and NeckDana M Hartl, Joanne Guerlain, Philippe Gorphe, et al.
The Oncologist|March 19, 2022
Comparison of the Seventh and Eighth Edition of American Joint Committee on Cancer (AJCC) Staging for Selected and Nonselected Oropharyngeal Squamous Cell CarcinomasPooja Vijayvargiya, Sumita Trivedi, Manali Rupji, et al.
The Lancet. Oncology|July 29, 2019
Palbociclib and cetuximab in platinum-resistant and in cetuximab-resistant human papillomavirus-unrelated head and neck cancer: a multicentre, multigroup, phase 2 trialDouglas Adkins, Jessica Ley, Prakash Neupane, et al.
Advances in Therapy|February 4, 2018
Head and Neck Cancer: A Review of the Impact of Treatment Delay on OutcomeAndrés Coca-Pelaz, Robert P Takes, Kate Hutcheson, et al.
Cancers|September 9, 2020
Gut Microbiome Associated with the Psychoneurological Symptom Cluster in Patients with Head and Neck CancersJinbing Bai, Deborah Watkins Bruner, Veronika Fedirko, et al.
Cancers|August 15, 2018
The Current Role of Salvage Surgery in Recurrent Head and Neck Squamous Cell CarcinomaMarc Hamoir, Sandra Schmitz, Carlos Suarez, et al.
Cancer Management and Research|February 4, 2022
Application of Artificial Intelligence for Nasopharyngeal Carcinoma Management - A Systematic ReviewWai Tong Ng, Barton But, Horace C W Choi, et al.
Cancers|June 22, 2023
Recurrent Differentiated Thyroid Cancer: The Current Treatment OptionsAndrés Coca-Pelaz, Juan Pablo Rodrigo, Jatin P Shah, et al.
Cancers|May 28, 2022
Phase II Trial of CDX-3379 and Cetuximab in Recurrent/Metastatic, HPV-Negative, Cetuximab-Resistant Head and Neck CancerJulie E Bauman, Ricklie Julian, Nabil F Saba, et al.
Pageof 39